Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vibecototamab + putilimab
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vibecototamab + putilimab is a combination therapy being evaluated for the treatment of EGFR-positive refractory advanced biliary tract malignancies. Vibecototamab (also known as MRG003) is an antibody-drug conjugate (ADC) composed of a humanized anti-EGFR monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Putilimab (also known as HLX10 or puzelimab) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor. The combination aims to leverage the targeted cytotoxicity of the ADC, which induces immunogenic cell death, and the immune-restoring capabilities of the PD-1 inhibitor to overcome resistance in advanced biliary tract cancers. This specific combination is being investigated in clinical trials led by West China Hospital.
- Other names
- vibecotecotamabpuzelimabviberceptvebecotototoputliVedotin-tislelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL3RA (Interleukin 3 Receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on vibecototamab + putilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vibecototamab + putilimab.